Omnicell, Inc. is a healthcare technology company providing medication management solutions, including storage and dispensing automation and an intelligence ecosystem. The company operates in two core market categories: Hospital and Health System Solutions, which unifies central pharmacy automation, robotics, and IV sterile compounding with point-of-care automated dispensing in nursing units and operating rooms; and Outpatient Pharmacy Solutions, which supports specialty pharmacy, 340B third-party administrator services, and medication adherence technologies. Omnicell serves hospitals, health systems, ambulatory care settings, long-term care facilities, correctional facilities, and behavioral health providers. The company offers the EnlivenHealth platform for medication adherence and clinical outcomes. Founded in 1992, Omnicell focuses on automating routine tasks to improve medication safety, workflow efficiency, and inventory visibility across the continuum of care.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage omnicell.com
Sector Healthcare IR page ir.omnicell.com/overview/default.aspx
Tags
medication management, pharmacy automation, automated dispensing, iv compounding, specialty pharmacy, 340b program, medication adherence, healthcare technology, inventory management, robotics, EnlivenHealth
Press page omnicell.com/resources/news

Metrics

Valuation  
Market cap $ 1.61B
Market cap (USD) $ 1.61B
P/E 36.46
PEG —
P/BV 1.22
P/S 1.29
P/OCF 8.64
P/FCF 11.04
Dividend yield —
Turnover / mcap —
Returns  
ROE 0.17%
ROI 0.15%
ROIC 0.18%
Profit margin 0.17%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -28.6%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) Yes
Debt/Equity 13.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 22
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 1.185B 1.112B 1.147B 1.296B 1.132B 892.208M 897.027M 787.309M 716.165M 692.623M 484.559M 440.9M 380.585M 314.027M 245.535M 222.407M 213.457M 251.865M 213.081M 154.71M 121.518M 123.939M 102.127M 87.69M 86.901M 67.365M
Net profit 2.052M 12.531M -20.371M 5.648M 77.849M 32.194M 61.338M 37.729M 20.605M 603K 30.76M 30.518M 23.979M 16.178M 10.389M 4.892M 444K 12.724M 43.295M 10.365M -2.074M 10.602M 7.307M -5.038M -1.167M -20.789M
Free cash flow 86.885M 151.259M 139.62M 30.245M 202.842M 163.028M 129.114M 80.269M 9.493M 34.492M 26.22M — 42.928M 24.283M 22.558M 13.708M 39.485M 7.405M 30.59M 16.398M -4.356M -8.083M 5.022M -890K -13.657M -19.619M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 45.3 44.52 37.63 50.42 180.44 120.02 81.72 61.24 48.5 33.9 31.08 33.12 25.53 14.88 16.74 14.44 11.76 12.2 26.52 18.69 10.58 10.28 — — — —
Price performance 12m 0.02 0.18 -0.25 -0.72 0.5 0.47 0.33 0.26 0.43 0.09 -0.06 0.3 0.72 -0.11 0.16 0.23 -0.04 -0.54 0.42 0.77 0.03 — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 150M 189M 196M 218M 190M 241M 299M 252M 256M 217M
↳ YoY growth +39.2% +25.9% +3.7% +11.3% -12.9% +26.7% +24.3% -15.8% +1.7% -15.4%
↳ 5y CAGR +32.4% +28.0% +27.3% +21.4% +12.0% +9.9% +9.6% +5.1% +3.3% +2.7%
Borrowings, current (USD) 8.41M 15.2M 0.00 — — — — — — —
Borrowings, non-current (USD) 246M 195M 135M 50M — — — — — —
Lease liabilities (USD) — — 0.00 60.8M 61.1M 52.9M 50.2M 44.4M 41.8M 36.7M
Cash and deposits (USD) 54.5M 32.4M 67.2M 127M 486M 349M 330M 468M 369M 197M
Intangible assets (USD) 190M 168M 144M 125M 168M 278M 243M 211M 188M 170M
Right-of-use assets (USD) — — 0.00 56.1M 55.1M 48.5M 38.1M 25M 25.6M 24.4M
Net debt (borrowings + leases - cash) (USD) 200M 178M 68.2M -16.4M — — — — — —
Cash flow detail
Operating cash flow (USD) 47.9M 24.8M 104M 145M 186M 232M 77.8M 181M 188M 127M
Purchases of property, plant and equipment (USD) -13.4M -15.3M -23.7M -15.9M -22.8M -29M -47.5M -41.5M -36.5M -40.4M
Purchases of intangible assets (USD) -1.37M -160,000 0.00 0.00 — — — — — —
Change in receivables (cash effect) (USD) 8.05M -39.1M -6.19M -21.5M 36.8M -41M -60.4M — — —
Change in inventories (cash effect) (USD) -3.36M -26.8M -6.76M -8.12M 12.4M -25.7M -30.1M 38M 15.6M -11.2M
Change in payables (cash effect) (USD) -4.96M 19.7M -9.15M 7.89M -6.3M 29.1M -7.75M -17.5M 7.21M -9.28M
Share buybacks (cash effect) (USD) 0.00 0.00 0.00 0.00 -53M 0.00 -52.2M 0.00 0.00 -77.6M
Interest paid (cash effect) (USD) -5.34M -6.55M -7.49M -3.58M -522,000 -1.92M -1.44M -1.44M -1.62M -2.2M
Income taxes paid (cash effect) (USD) -11.1M -7.78M -3.49M -7.76M -10.3M 1.73M -19M -20.2M -11.3M -18.4M
Share-based compensation (USD) 19.5M 21.9M 28.9M 34M 44.7M 53.2M 68.2M 55.3M 39.3M 44.5M
Operating cash flow before change in receivables (USD) 39.9M 63.9M 110M 167M 149M 273M 138M — — —
Free cash flow (OCF - PPE - intangibles) (USD) 33.1M 9.33M 80.3M 129M 163M 203M 30.2M 140M 151M 86.9M
Income detail
Research and development expense (USD) 57.8M 66M 64.8M 68.6M 70.2M 75.7M 105M 97.1M 90.4M 88.7M
↳ 5y CAGR +21.3% +22.7% +17.4% +19.8% +14.8% +5.5% +9.7% +8.4% +5.7% +4.8%
Total comprehensive income (USD) -6.19M 24M 33M 62.7M 36.1M 75M -3.03M -16.7M 8.77M 10.4M
Comprehensive income to owners (USD) -6.19M 24M 33M 62.7M 36.1M 75M -3.03M -16.7M 8.77M 10.4M
Reported Feb 28, 2017 Feb 27, 2018 Feb 24, 2021 Feb 24, 2021 Feb 24, 2021 Feb 25, 2022 Mar 1, 2023 Feb 28, 2024 Feb 27, 2025 Feb 26, 2026

Operating KPIs — quarters

KPI Dec 21 Dec 22 Dec 23 Dec 24
Backlog / order book (USD) 1.25B 1.22B 1.14B 1.2B
↳ YoY growth -3.1% -6.0% +5.1%
Reported Feb 28, 2023 Feb 28, 2023 Feb 8, 2024 Feb 6, 2025

Operating KPIs — years

KPI Dec 2021 Dec 2022 Dec 2023 Dec 2024
Backlog / order book (USD) 1.25B 1.22B 1.14B 1.2B
↳ YoY growth -3.1% -6.0% +5.1%
Reported Feb 28, 2023 Feb 28, 2023 Feb 8, 2024 Feb 6, 2025

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

David Unger 4220 North Freeway Bull 4 Bear 0 Results

Vice President, Investor Relations Fort Worth, TX 76137

[email protected]

Omnicell Announces Third Quarter 2026 Financial Results

Omnicell delivers solid third quarter 2026 financial results

Updates full year 2026 guidance

FORT WORTH, Texas -- October 29, 2026 -- Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” or the “Company”), a healthcare technology leader focused on advancing autonomous medication management, today reported financial results for the third quarter ended September 30, 2026.

Third quarter results reflected continued execution across the business, supported by demand for Omnicell’s connected device portfolio, favorable product and service margins and disciplined cost management. Our business performed well during the quarter, with revenue and profitability both coming in above the high end of our previously provided guidance range, and we continue to see healthcare providers prioritize solutions that are designed to improve operational efficiency, optimize medication workflows, and help address ongoing workforce challenges.

“We delivered solid third quarter results and continued to execute against our strategic priorities,” said Randall A.

October 29, 2026

Omnicell delivers solid third quarter 2026 financial results

Updates full year 2026 guidance

FORT WORTH, Texas--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” or the “Company”), a healthcare technology leader focused on advancing autonomous medication management, today reported financial results for the third quarter ended September 30, 2026.

Third quarter results reflected continued execution across the business, supported by demand for Omnicell’s connected device portfolio, favorable product and service margins and disciplined cost management. Our business performed well during the quarter, with revenue and profitability both coming in above the high end of our previously provided guidance range, and we continue to see healthcare providers prioritize solutions that are designed to improve operational efficiency, optimize medication workflows, and help address ongoing workforce challenges.

“We delivered solid third quarter results and continued to execute against our strategic priorities,” said Randall A. Lipps, chairman, chief executive officer, and founder of Omnicell. “We believe our performance reflects the discipline we have built into the business throughout the year, combined with continued customer interest in solutions that are designed to improve efficiency, safety, and workforce productivity across medication management.”

“At the same time, we continue to see strong momentum with our next-generation platform, backed by a growing pipeline,” Lipps added. “Customers are validating the potential value of combining Titan XT with OmniSphere, our cloud-native platform, intended to improve productivity, efficiency, and workflow reliability. As we see health systems seek greater visibility and connectivity across the medication-use process, we believe Omnicell Titan XT and OmniSphere position us to capitalize on a significant long-term opportunity we see in autonomous medication management.”

Financial Results

Total revenues for the third quarter of 2026 were $308 million, down $3 million, or 1%, from the third quarter of 2025.

Total GAAP net income for the third quarter of 2026 was $11 million, or $0.24 per diluted share. This compares to GAAP net income of $5 million, or $0.12 per diluted share, for the third quarter of 2025.

Total non-GAAP net income for the third quarter of 2026 was $27 million, or $0.58 per diluted share. This compares to non-GAAP net income of $24 million, or $0.51 per diluted share, for the third quarter of 2025.

Total non-GAAP EBITDA for the third quarter of 2026 was $45 million. This compares to non-GAAP EBITDA of $41 million for the third quarter of 2025.

Balance Sheet

As of September 30, 2026, Omnicell’s balance sheet reflected cash and cash equivalents of $315 million, total debt (net of unamortized debt issuance costs) of $169 million, and total assets of $2.1 billion. Cash flows provided by operating activities in the third quarter of 2026 totaled $33 million. This compares to cash flows provided by operating activities totaling $28 million in the third quarter of 2025.

As of September 30, 2026, the Company had $350 million of availability under its revolving credit facility with no outstanding balance.

Corporate Highlights

  • Over 200 healthcare leaders and industry experts joined Omnicell for the sixth annual Illuminate, a virtual education and best practice sharing event. Panel discussions focused on real-world experiences building connected, intelligent medication management strategies that are designed to help drive meaningful clinical, operational, and financial outcomes.
  • Issued the 2025 Environmental, Social, and Governance (ESG) Report, which reflects Omnicell’s ongoing commitment to ESG principles. Guided by innovation, the Report highlights the Company’s continuous focus on advancing autonomous medication management while supporting a more sustainable and patient-centered healthcare ecosystem.

2026 Guidance

The table below summarizes Omnicell’s fourth quarter and updated full year 2026 guidance. Given our strong third quarter 2026 profitability performance and continued focus on disciplined execution, we are increasing our full year 2026 non-GAAP EBITDA and non-GAAP earnings per share guidance ranges. In addition, as we are through the first three quarters of the year, we are tightening our full year 2026 total, product, and service revenues guidance ranges. We are also tightening our full year 2026 annual recurring revenue guidance range, with the low end unchanged, reflecting our increased visibility into the business as we approach year end. We are reiterating our product bookings guidance range, which continues to reflect our current assessment of the range of potential outcomes for full year 2026.

Q4 2026 2026
Product Bookings Not provided $425 million - $560 million
Annual Recurring Revenue Not provided $660 million - $670 million
Total Revenues $295 million - $301 million $1.225 billion - $1.231 billion
Product Revenues $161 million - $164 million $684 million - $687 million
Service Revenues $134 million - $137 million $541 million - $544 million
Technical Services Revenues Not provided $272 million - $273 million
SaaS and Expert Service Revenues Not provided $269 million - $271 million
Non-GAAP EBITDA $30 million - $36 million $187 million - $193 million
Non-GAAP Earnings Per Share $0.41 - $0.49 $2.48 - $2.56

The Company does not provide guidance for GAAP net income or GAAP earnings per share, nor a reconciliation of any forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures on a forward-looking basis because it is unable to predict certain items contained in the GAAP measures without unreasonable efforts. These forward-looking non-GAAP financial measures do not include certain items, which may be significant, including, but not limited to, unusual gains and losses, costs associated with future restructurings, acquisition-related expenses, and certain tax and litigation outcomes.

Omnicell Conference Call Information

Omnicell will hold a conference call today, Thursday, October 29, 2026, at 8:30 a.m. ET to discuss third quarter 2026 financial results. The conference call can be monitored by dialing (833) 461-5787 in the U.S. or (585) 542-9983 in international locations. The Conference ID is 574173299. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell’s website at https://ir.omnicell.com/events-and-presentations/ .

About Omnicell

Omnicell is a healthcare technology leader focused on advancing autonomous medication management to drive meaningful outcomes across the patient care journey. Through AI-enabled innovation, enterprise intelligence, and scalable automation, we seek to connect and optimize medication management from orders to outcomes, empowering healthcare organizations worldwide to improve efficiency, enhance safety, strengthen financial performance, and deliver better experiences for patients and care teams. Learn more at omnicell.com.

From time to time, Omnicell may use the Company’s investor relations website and other online social media channels, including its LinkedIn page www.linkedin.com/company/omnicell , and Facebook page www.facebook.com/omnicellinc , to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure (“Reg FD”).

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries. This press release may also include the trademarks and service marks of other companies. Such trademarks and service marks are the marks of their respective owners.

Forward-Looking Statements

To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control.

Such statements include, but are not limited to, Omnicell’s projected product bookings, revenues, including product, service, technical services and SaaS and Expert Services revenues, annual recurring revenue, non-GAAP EBITDA, and non-GAAP earnings per share; expectations regarding demand for, and customer interest in, our products and services, developing new or enhancing existing products and solutions and the related objectives and expected benefits (and any implied financial impact); Omnicell’s ability to maintain focus on operational discipline and execute against its strategic priorities; the ability for our next-generation platform to support our customers’ needs; the long-term opportunity the next-generation platform represents, and statements about Omnicell’s strategy, plans, objectives, promise and purpose, vision, goals, opportunities, and market or Company outlook.

Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including longer timeframes for purchasing decisions and entering into agreements for our products or solutions, (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (iv) Omnicell’s ability to successfully achieve anticipated growth targets or market adoption, (v) delays in installations of our medication management solutions or our more complex medication packaging systems, including the variability and difficulty in predicting purchasing decisions, for both current customers and competitive conversion opportunities being, difficulty forecasting product bookings due to the size and mix of potential customer opportunities or that the announcement of Titan XT may influence or impact purchasing decisions, including the timing of those decisions, (vi) delays, technical challenges and unexpected or greater than anticipated expenses associated with developing new products and services or failing to achieve technological or economic feasibility, obtain regulatory approval or gain market acceptance, (vii) the potential impact of periods of significant volatility due to geopolitical developments, (viii) the risk of increased credit, collection, and operational challenges from providing lease financing options to our customers, (ix) risks related to the incorporation of artificial intelligence technologies, including generative or agentic AI technologies, into our products, services and processes or our vendors offerings, (x) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (xi) risks related to failing to maintain expected service levels when providing our SaaS and Expert Services or retaining our SaaS and Expert Services customers, (xii) Omnicell’s ability to meet the demands of, or maintain relationships with, GPOs and its institutional, retail, and specialty pharmacy customers, (xiii) the inability to secure or maintain access to existing and future specialty drugs or pharmacy provider networks for our specialty pharmacy customers, (xiv) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (xv) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, and its ability to acquire companies, businesses or technologies and successfully integrate such acquisitions, (xvi) Omnicell’s substantial debt, (xvii) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity related to the same, (xviii) changes to the 340B Program, (xix) our international operations may subject us to additional risks, including from the impact of tariffs, (xx) covenants in our credit agreement could restrict our business and operations, (xxi) exposure to liquidity and counterparty risk as a result of financial institution and money market fund concentration, (xxii) risks related to climate change, legal, regulatory or market measures to address climate change and related emphasis on ESG matters by various stakeholders, (xxiii) catastrophic events, (xxiv) Omnicell’s ability to recruit and retain skilled and motivated personnel, (xxv) Omnicell’s ability to protect its intellectual property, (xxvi) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xxvii) Omnicell’s dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, (xxviii) fluctuations in quarterly and annual operating results may make our future operating results difficult to predict, (xxix) failing to meet (or significantly exceeding) our publicly announced financial guidance, and (xxx) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov . Forward-looking statements should be considered in light of these risks and uncertainties. Readers are encouraged to review this press release in conjunction with our most recent Annual Report on Form 10-K and our other reports filed with or furnished to the SEC. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Management evaluates and makes operating decisions using various performance measures. In addition to Omnicell’s GAAP results, we also consider non-GAAP product gross profit, non-GAAP product gross margin, non-GAAP service gross profit, non-GAAP service gross margin, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP diluted shares, non-GAAP EBITDA, non-GAAP EBITDA margin, and non-GAAP free cash flow. These non-GAAP results and metrics should not be considered as an alternative to revenues, product gross profit, service gross profit, gross profit, operating expenses, income from operations, net income, net income per diluted share, diluted shares, net cash provided by operating activities, or any other performance measure derived in accordance with GAAP. We present these non-GAAP results and metrics because management considers them to be important supplemental measures of Omnicell’s performance and refers to such measures when analyzing Omnicell’s strategy and operations.

Our non-GAAP product gross profit, non-GAAP product gross margin, non-GAAP service gross profit, non-GAAP service gross margin, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP EBITDA, and non-GAAP EBITDA margin are exclusive of certain items to facilitate management’s review of the comparability of Omnicell’s core operating results on a period-to-period basis because such items are not related to Omnicell’s ongoing core operating results as viewed by management. We define our “core operating results” as those revenues recorded in a particular period and the expenses incurred within such period that directly drive operating income in such period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we believe we should invest in research and development, fund infrastructure growth, and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results: non-GAAP product gross profit and non-GAAP product gross margin exclude from their GAAP equivalents items a), b), and h) below; non-GAAP service gross profit and non-GAAP service gross margin exclude from their GAAP equivalents a), b), and j) below; non-GAAP gross profit and non-GAAP gross margin exclude from their GAAP equivalents items a), b), h) and j) below; non-GAAP operating expenses, non-GAAP income from operations and non-GAAP operating margin exclude from their GAAP equivalents items a), b), c), e), f), g), h), i), j) and k) below; and non-GAAP net income and non-GAAP net income per diluted share exclude from their GAAP equivalents items a) through k) below. Non-GAAP EBITDA is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. Non-GAAP EBITDA and non-GAAP EBITDA margin exclude from their GAAP equivalents items a), c), d), e), f), g), h), i), j) and k) below:

a) Share-based compensation expense. We excluded from our non-GAAP results the expense related to equity-based compensation plans as it represents expenses that do not require cash settlement from Omnicell.
b) Amortization of acquired intangible assets. We excluded from our non-GAAP results the intangible assets amortization expense resulting from our past acquisitions. These non-cash charges are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results.
c) Acquisition-related expenses. We excluded from our non-GAAP results the expenses related to recent acquisitions, including amortization of representations and warranties insurance. These expenses are unrelated to our ongoing operations, vary in size and frequency, and are subject to significant fluctuations from period to period due to varying levels of acquisition activity. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
d) Amortization of debt issuance costs. Debt issuance costs represent costs associated with the issuance of revolving credit facilities and convertible senior notes. The costs include underwriting fees, original issue discount, ticking fees, and legal fees. These non-cash expenses are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results.
e) Legal and regulatory expenses. We excluded from our non-GAAP results certain non-recurring legal and regulatory expenses, representing settlement amounts, related to certain claims of non-compliance with our government contracts that are outside of the ordinary course of our business. We believe that excluding these amounts provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
f) Management severance costs. We excluded from our non-GAAP results the severance expense of certain senior management associated with the restructuring of our senior leadership team. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
g) Executives transition costs. We excluded from our non-GAAP results the transition costs associated with the departure of a certain executive officer, primarily consisting of severance expenses. These expenses are unrelated to our ongoing operations and we do not expect them to occur in the ordinary course of business. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
h) Professional Services restructuring costs. We excluded from our non-GAAP results nonrecurring restructuring charges related to organizational and resource adjustments within Professional Services to improve scalability and better align with evolving customer needs. These expenses are unrelated to our ongoing operations and we believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
i) Product organization restructuring costs. We excluded from our non-GAAP results the nonrecurring charges related to the restructuring of the product organization to better align teams, resources, and priorities with our strategic goals and future growth plans. These charges consisted primarily of severance and other related expenses. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
j) EnlivenHealth restructuring costs. We excluded from our non-GAAP results the nonrecurring charges primarily related to restructuring within the EnlivenHealth business as we seek to gain operational efficiency and synergy, and adapt to the recent industry dynamics within the retail pharmacy space. These charges consisted primarily of severance and other related expenses. These expenses are unrelated to our ongoing operations and we believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
k) China restructuring costs. We excluded from our non-GAAP results the nonrecurring restructuring charges related to the exit of our Beijing, China office as part of our operating model adjustments. These charges consisted primarily of severance and other related expenses. These expenses are unrelated to our ongoing operations and we believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.

Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell’s control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational or non-cash expenses involving stock compensation plans or other items.

We believe that the presentation of non-GAAP product gross profit, non-GAAP product gross margin, non-GAAP service gross profit, non-GAAP service gross margin, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP EBITDA, and non-GAAP EBITDA margin is warranted for several reasons:

a) Such non-GAAP financial measures provide an additional analytical tool for understanding Omnicell’s financial performance by excluding the impact of items which may obscure trends in the core operating results of the business.
b) Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors’ ability to compare our performance across financial reporting periods.
c) These non-GAAP financial measures are employed by management in its own evaluation of performance and are utilized in financial and operational decision-making processes, such as budget planning and forecasting.
d) These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which also use non-GAAP financial measures to supplement their GAAP results (although these companies may calculate non-GAAP financial measures differently than Omnicell does), thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance.

Set forth below are additional reasons why share-based compensation expense is excluded from our non-GAAP financial measures:

i) While share-based compensation calculated in accordance with Accounting Standards Codification (“ASC”) 718 constitutes an ongoing and recurring expense of Omnicell, it is not an expense that requires cash settlement by Omnicell. We therefore exclude these charges for purposes of evaluating core operating results. Thus, our non-GAAP measurements are presented exclusive of share-based compensation expense to assist management and investors in evaluating our core operating results.
ii) We present ASC 718 share-based payment compensation expense in our reconciliation of non-GAAP financial measures on a pre-tax basis because the exact tax differences related to the timing and deductibility of share-based compensation under ASC 718 are dependent upon the trading price of Omnicell’s common stock and the timing and exercise by employees of their stock options. As a result of these timing and market uncertainties, the tax effect related to share-based compensation expense would be inconsistent in amount and frequency and is therefore excluded from our non-GAAP results.

Non-GAAP diluted shares is defined as our GAAP diluted shares, excluding the impact of dilutive convertible senior notes for which the Company is economically hedged through its anti-dilutive convertible note hedge transaction. Additionally, in a period of net loss, GAAP diluted shares are further adjusted for certain shares whose effect would be dilutive in a period of net income. We believe non-GAAP diluted shares is a useful non-GAAP metric because it provides insight into the offsetting economic effect of the hedge transaction against potential conversion of the convertible senior notes.

Non-GAAP free cash flow is defined as net cash provided by operating activities less cash used for software development for external use and purchases of property and equipment. We believe free cash flow is important to enable investors to better understand and evaluate our ongoing operating results and allows for greater transparency in the review and understanding of our overall financial, operational, and economic performance, because free cash flow takes into account certain capital expenditures and cash used for software development necessary to operate our business.

As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell’s GAAP results. In the future, we expect to incur expenses similar to certain of the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are:

a) Omnicell’s equity incentive plans and stock purchase plans are important components of incentive compensation arrangements and will be reflected as expenses in Omnicell’s GAAP results for the foreseeable future under ASC 718.
b) Other companies, including companies in Omnicell’s industry, may calculate non-GAAP financial measures differently than Omnicell, limiting their usefulness as a comparative measure.
c) A limitation of the utility of free cash flow as a measure of financial performance is that it does not represent the total increase or decrease in Omnicell’s cash balance for the period.

A detailed reconciliation between Omnicell’s non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release as well as in Omnicell’s other reports filed with or furnished to the SEC.

Omnicell, Inc.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except per share data)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Revenues:
Product revenues $ 173,052 $ 177,498 $ 522,914 $ 485,838
Service revenues 134,799 133,133 407,025 385,023
Total revenues 307,851 310,631 929,939 870,861
Cost of revenues:
Cost of product revenues 98,222 96,741 279,408 274,245
Cost of service revenues 71,803 79,387 219,407 223,499
Total cost of revenues 170,025 176,128 498,815 497,744
Gross profit 137,826 134,503 431,124 373,117
Operating expenses:
Research and development 22,352 24,021 64,170 66,120
Selling, general, and administrative 100,541 102,238 302,718 302,252
Total operating expenses 122,893 126,259 366,888 368,372
Income from operations 14,933 8,244 64,236 4,745
Interest and other income (expense), net 871 1,459 2,306 5,881
Income before income taxes 15,804 9,703 66,542 10,626
Provision for income taxes 4,760 4,241 19,851 6,548
Net income $ 11,044 $ 5,462 $ 46,691 $ 4,078
Net income per share:
Basic $ 0.24 $ 0.12 $ 1.02 $ 0.09
Diluted $ 0.24 $ 0.12 $ 1.01 $ 0.09
Weighted-average shares outstanding:
Basic 45,893 45,540 45,610 46,304
Diluted 46,466 45,900 46,269 46,657
Omnicell, Inc.
Condensed Consolidated Balance Sheets
(Unaudited, in thousands)
September 30, 2026 December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents $ 314,856 $ 196,520
Accounts receivable and unbilled receivables, net 236,046 216,858
Inventories 98,278 100,905
Prepaid expenses 50,631 33,709
Other current assets 84,170 132,077
Total current assets 783,981 680,069
Property and equipment, net 124,302 120,111
Long-term investment in sales-type leases, net 67,302 60,742
Operating lease right-of-use assets 23,097 24,366
Goodwill 737,125 737,946
Intangible assets, net 156,373 170,105
Long-term deferred tax assets 44,886 58,337
Prepaid commissions 52,623 52,840
Other long-term assets 67,147 70,204
Total assets $ 2,056,836 $ 1,974,720
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 60,824 $ 43,990
Accrued compensation 68,335 57,172
Accrued liabilities 144,749 203,586
Deferred revenues 199,789 171,861
Total current liabilities 473,697 476,609
Long-term deferred revenues 63,792 63,254
Long-term deferred tax liabilities 640 683
Long-term operating lease liabilities 21,161 24,794
Other long-term liabilities 11,783 9,970
Convertible senior notes, net 168,508 167,596
Total liabilities 739,581 742,906
Total stockholders’ equity 1,317,255 1,231,814
Total liabilities and stockholders’ equity $ 2,056,836 $ 1,974,720
Omnicell, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)
Nine Months Ended September 30,
2026 2025
Operating Activities
Net income $ 46,691 $ 4,078
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 55,812 58,984
Loss on disposal of assets 440 408
Share-based compensation expense 33,122 32,526
Deferred income taxes 13,408 1,233
Amortization of operating lease right-of-use assets 5,762 5,868
Impairment of external-use software development costs 122 —
Amortization of debt issuance costs 1,494 2,155
Changes in operating assets and liabilities:
Accounts receivable and unbilled receivables (19,188 ) 12,450
Inventories 2,627 (17,731 )
Prepaid expenses (16,922 ) (4,305 )
Other current assets (12,611 ) (10,037 )
Investment in sales-type leases (8,212 ) (2,493 )
Prepaid commissions 217 2,097
Other long-term assets (2,673 ) 5,919
Accounts payable 18,245 10,695
Accrued compensation 11,163 (10,999 )
Accrued liabilities 4,805 (13,059 )
Deferred revenues 28,737 26,901
Operating lease liabilities (8,986 ) (8,753 )
Other long-term liabilities 1,813 1,009
Net cash provided by operating activities 155,866 96,946
Investing Activities
External-use software development costs (8,765 ) (13,237 )
Purchases of property and equipment (32,738 ) (32,706 )
Net cash used in investing activities (41,503 ) (45,943 )
Financing Activities
Repayment of convertible senior notes due 2025 — (175,000 )
Proceeds from issuances under stock-based compensation plans 14,014 15,162
Employees’ taxes paid related to restricted stock units (7,826 ) (5,963 )
Excise tax paid on common stock repurchases (388 ) —
Common stock repurchases — (77,600 )
Change in customer funds, net (31,713 ) 15,989
Net cash used in financing activities (25,913 ) (227,412 )
Effect of exchange rate changes on cash and cash equivalents (1,827 ) 3,250
Net increase (decrease) in cash, cash equivalents, and restricted cash 86,623 (173,159 )
Cash, cash equivalents, and restricted cash at beginning of period 251,032 398,614
Cash, cash equivalents, and restricted cash at end of period $ 337,655 $ 225,455
Reconciliation of cash, cash equivalents, and restricted cash to the Condensed Consolidated Balance Sheets:
Cash and cash equivalents $ 314,856 $ 180,053
Restricted cash included in other current assets 22,799 45,402
Cash, cash equivalents, and restricted cash at end of period $ 337,655 $ 225,455
Omnicell, Inc.
Reconciliation of GAAP to Non-GAAP
(Unaudited, in thousands, except per share data and percentage)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Reconciliation of GAAP product gross profit to non-GAAP product gross profit:
GAAP product revenues $ 173,052 $ 177,498 $ 522,914 $ 485,838
GAAP cost of product revenues 98,222 96,741 279,408 274,245
GAAP product gross profit $ 74,830 $ 80,757 $ 243,506 $ 211,593
GAAP product gross margin 43.2 % 45.5 % 46.6 % 43.6 %
Share-based compensation expense 601 277 1,850 1,721
Amortization of acquired intangibles 333 332 998 1,014
Professional Services restructuring — — 1,630 —
Non-GAAP product gross profit $ 75,764 $ 81,366 $ 247,984 $ 214,328
Non-GAAP product gross margin 43.8 % 45.8 % 47.4 % 44.1 %
Reconciliation of GAAP service gross profit to non-GAAP service gross profit:
GAAP service revenues $ 134,799 $ 133,133 $ 407,025 $ 385,023
GAAP cost of service revenues 71,803 79,387 219,407 223,499
GAAP service gross profit $ 62,996 $ 53,746 $ 187,618 $ 161,524
GAAP service gross margin 46.7 % 40.4 % 46.1 % 42.0 %
Share-based compensation expense 817 719 2,472 2,200
Amortization of acquired intangibles 289 654 908 1,966
EnlivenHealth restructuring — 892 — 892
Non-GAAP service gross profit $ 64,102 $ 56,011 $ 190,998 $ 166,582
Non-GAAP service gross margin 47.6 % 42.1 % 46.9 % 43.3 %
Reconciliation of GAAP gross profit to non-GAAP gross profit:
GAAP gross profit $ 137,826 $ 134,503 $ 431,124 $ 373,117
GAAP gross margin 44.8 % 43.3 % 46.4 % 42.8 %
Share-based compensation expense 1,418 996 4,322 3,921
Amortization of acquired intangibles 622 986 1,906 2,980
Professional Services restructuring — — 1,630 —
EnlivenHealth restructuring — 892 — 892
Non-GAAP gross profit $ 139,866 $ 137,377 $ 438,982 $ 380,910
Non-GAAP gross margin 45.4 % 44.2 % 47.2 % 43.7 %
Reconciliation of GAAP operating expenses to non-GAAP operating expenses:
GAAP operating expenses $ 122,893 $ 126,259 $ 366,888 $ 368,372
GAAP operating expenses % to total revenues 39.9 % 40.6 % 39.5 % 42.3 %
Share-based compensation expense (9,999 ) (10,214 ) (28,800 ) (28,605 )
Amortization of acquired intangibles (3,840 ) (4,248 ) (11,715 ) (13,283 )
Acquisition-related expenses (182 ) (182 ) (546 ) (546 )
China restructuring (652 ) — (652 ) —
Professional Services restructuring — — (131 ) —
Product organization restructuring — — (1,929 ) —
EnlivenHealth restructuring — (1,674 ) — (1,674 )
Legal and regulatory expenses — — — (2,700 )
Management severance costs — — — (562 )
Executives transition costs — — — (968 )
Non-GAAP operating expenses $ 108,220 $ 109,941 $ 323,115 $ 320,034
Non-GAAP operating expenses as a % of total revenues 35.2 % 35.4 % 34.7 % 36.7 %
Omnicell, Inc.
Reconciliation of GAAP to Non-GAAP
(Unaudited, in thousands, except per share data and percentage)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Reconciliation of GAAP income from operations to non-GAAP income from operations:
GAAP income from operations $ 14,933 $ 8,244 $ 64,236 $ 4,745
GAAP operating income % to total revenues 4.9 % 2.7 % 6.9 % 0.5 %
Share-based compensation expense 11,417 11,210 33,122 32,526
Amortization of acquired intangibles 4,462 5,234 13,621 16,263
Acquisition-related expenses 182 182 546 546
China restructuring 652 — 652 —
Professional Services restructuring — — 1,761 —
Product organization restructuring — — 1,929 —
EnlivenHealth restructuring — 2,566 — 2,566
Legal and regulatory expenses — — — 2,700
Management severance costs — — — 562
Executives transition costs — — — 968
Non-GAAP income from operations $ 31,646 $ 27,436 $ 115,867 $ 60,876
Non-GAAP operating margin (non-GAAP operating income as a % of total revenues) 10.3 % 8.8 % 12.5 % 7.0 %
Reconciliation of GAAP net income to non-GAAP net income:
GAAP net income $ 11,044 $ 5,462 $ 46,691 $ 4,078
Share-based compensation expense 11,417 11,210 33,122 32,526
Amortization of acquired intangibles 4,462 5,234 13,621 16,263
Acquisition-related expenses 182 182 546 546
China restructuring 652 — 652 —
Professional Services restructuring — — 1,761 —
Product organization restructuring — — 1,929 —
EnlivenHealth restructuring — 2,566 — 2,566
Legal and regulatory expenses — — — 2,700
Management severance costs — — — 562
Executives transition costs — — — 968
Amortization of debt issuance costs 499 694 1,494 2,155
Tax effect of the adjustments above(a) (1,217 ) (1,822 ) (4,201 ) (5,410 )
Non-GAAP net income $ 27,039 $ 23,526 $ 95,615 $ 56,954
__________________________
(a) Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2026 and 2025.
Omnicell, Inc.
Reconciliation of GAAP to Non-GAAP
(Unaudited, in thousands, except per share data and percentage)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Reconciliation of GAAP net income per share - diluted to non-GAAP net income per share - diluted:
Shares - diluted GAAP 46,466 45,900 46,269 46,657
Shares - diluted non-GAAP 46,466 45,900 46,269 46,657
GAAP net income per share - diluted $ 0.24 $ 0.12 $ 1.01 $ 0.09
Share-based compensation expense 0.25 0.24 0.73 0.70
Amortization of acquired intangibles 0.10 0.11 0.29 0.35
Acquisition-related expenses 0.00 0.00 0.01 0.01
China restructuring 0.01 — 0.01 —
Professional Services restructuring — — 0.04 —
Product organization restructuring — — 0.04 —
EnlivenHealth restructuring — 0.06 — 0.05
Legal and regulatory expenses — — — 0.06
Management severance costs — — — 0.01
Executives transition costs — — — 0.02
Amortization of debt issuance costs 0.01 0.02 0.03 0.05
Tax effect of the adjustments above(a) (0.03 ) (0.04 ) (0.09 ) (0.12 )
Non-GAAP net income per share - diluted $ 0.58 $ 0.51 $ 2.07 $ 1.22
Reconciliation of GAAP net income to non-GAAP EBITDA(b):
GAAP net income $ 11,044 $ 5,462 $ 46,691 $ 4,078
Share-based compensation expense 11,417 11,210 33,122 32,526
Interest (income) and expense, net (2,031 ) (2,625 ) (5,045 ) (8,533 )
Depreciation and amortization expense 18,408 19,402 55,812 58,984
Acquisition-related expenses 182 182 546 546
China restructuring 652 — 652 —
Professional Services restructuring — — 1,761 —
Product organization restructuring — — 1,929 —
EnlivenHealth restructuring — 2,566 — 2,566
Legal and regulatory expenses — — — 2,700
Management severance costs — — — 562
Executives transition costs — — — 968
Amortization of debt issuance costs 499 694 1,494 2,155
Provision for income taxes 4,760 4,241 19,851 6,548
Non-GAAP EBITDA $ 44,931 $ 41,132 $ 156,813 $ 103,100
Non-GAAP EBITDA margin (non-GAAP EBITDA as a % of total revenues) 14.6 % 13.2 % 16.9 % 11.8 %
__________________________
(a) Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2026 and 2025.
(b) Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments.
Omnicell, Inc.
Reconciliation of GAAP to Non-GAAP
(Unaudited, in thousands)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Reconciliation of GAAP net cash provided by operating activities to non-GAAP free cash flow:
GAAP net cash provided by operating activities $ 33,052 $ 28,267 $ 155,866 $ 96,946
External-use software development costs (1,742 ) (4,528 ) (8,765 ) (13,237 )
Purchases of property and equipment (11,363 ) (9,753 ) (32,738 ) (32,706 )
Non-GAAP free cash flow $ 19,947 $ 13,986 $ 114,363 $ 51,003

David Unger
Vice President, Investor Relations
[email protected]

Source: Omnicell, Inc.

View All News

Investor
Resources

Investor Contact

Omnicell, Inc.

[email protected]

Quick Links

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Omnicell, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Omnicell to send you the requested Investor Email Alert updates.

* Required

Email * Investor Alert Options *

Press Release
Events & Presentations
Quarterly Reports
Annual Reports
SEC Filings
Stock Quote
Unsubscribe

Submit Submit

Email Alert Sign Up Confirmation

Defining. Delivering. Outcomes.

Care Settings

Resources

Company

Omnicell Logo

October 8, 2026

FORT WORTH, Texas--(BUSINESS WIRE)-- Omnicell, Inc. (Nasdaq:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the third quarter 2026, before market open on Thursday, October 29, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.

All interested parties are invited to listen to the live call and presentation by dialing (833) 461-5787 in the U.S. or (585) 542-9983 in international locations. The Conference ID is 574173299. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell’s website at https://ir.omnicell.com/events-and-presentations/ .

About Omnicell

Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities worldwide. Learn more at omnicell.com .

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

Investor Relations Contact
David Unger
VP, Investor Relations
Omnicell, Inc.
[email protected]

Source: Omnicell, Inc.

View All News

Investor
Resources

Investor Contact

Omnicell, Inc.

[email protected]

Quick Links

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Omnicell, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Omnicell to send you the requested Investor Email Alert updates.

* Required

Email * Investor Alert Options *

Press Release
Events & Presentations
Quarterly Reports
Annual Reports
SEC Filings
Stock Quote
Unsubscribe

Submit Submit

Email Alert Sign Up Confirmation

Defining. Delivering. Outcomes.

Care Settings

Resources

Company

Omnicell Logo

Prompts

Omnicell, Inc. (ticker OMCL), listed in United States.

ETFs Holding Omnicell, Inc.

ETF Weight in ETF Shares Market value As of
LITL 0.50% 840 $ 28.56K Nov 17, 2026
LGHT 0.45% 271 $ 11.252K Jun 30, 2026
SMIZ 0.28% 21,505 $ 756.116K Aug 31, 2026
FESM 0.24% 338,251 $ 14.044M Jun 30, 2026
ESSC 0.23% 2,383 $ 84.287K Jul 31, 2026
AFSM 0.23% 9,445 $ 334.731K Nov 16, 2026
SQLV 0.17% 1,193 $ 49.533K Jun 30, 2026
FTKI 0.15% 1,103 $ 39.09K Nov 16, 2026
MKTN 0.13% 3,421 $ 142.04K Jun 30, 2026
SMDX 0.13% 4,738 $ 167.915K Nov 17, 2026
PSC 0.12% 68,244 $ 2.833M Jun 30, 2026
DFSV 0.11% 875,923 $ 30.614M Nov 12, 2026
AVSC 0.11% 95,733 $ 3.393M Nov 16, 2026
SCDS 0.10% 270 $ 9,180.00 Nov 17, 2026
RUSC 0.10% 1,909 $ 79.262K Jun 30, 2026
RESM 0.08% 75 $ 3,114.00 Jun 30, 2026
SEIS 0.06% 8,845 $ 367.244K Jun 30, 2026
BSVO 0.06% 40,036 $ 1.36M Nov 18, 2026
DFAT 0.06% 529,058 $ 18.491M Nov 12, 2026
VFVA 0.04% 10,764 $ 378.462K Aug 31, 2026
VFMF 0.04% 10,820 $ 380.431K Aug 31, 2026
DFAS 0.04% 345,574 $ 12.078M Nov 12, 2026
JMEE 0.03% 27,002 $ 918.068K Nov 17, 2026
DXUV 0.01% 23,241 $ 812.273K Nov 12, 2026
MSSM 0.01% 2,456 $ 86.353K Aug 31, 2026
DFSU 0.01% 5,905 $ 206.38K Nov 12, 2026
DFAC 0.01% 207,359 $ 7.247M Nov 12, 2026
DFUV 0.01% 22,614 $ 790.359K Nov 12, 2026
DCOR 0.00% 55,902 $ 1.954M Nov 12, 2026
DFAU 0.00% 10,395 $ 363.305K Nov 12, 2026
DFUS 0.00% 14,436 $ 504.538K Nov 12, 2026
EBI 0.00% 111 $ 3,902.76 Aug 31, 2026
AVUS 0.00% 8,916 $ 315.983K Nov 16, 2026
AVSU 0.00% 83 $ 2,941.52 Nov 16, 2026